Gene signatures for cancer prognosis

1. Signature Blue_TNBC for triple-negative breast cancer

An analysis of over 60,000 cancer patients demonstrates that this gene signature is associated with the prognosis of multiple cancers, such as lung cancer, and shows particularly strong predictive power in ER-negative breast cancer, including TNBC  (Figs. 1-6).   Blue_TNBC also predicts survival in HER2-Enriched breast cancer (used here as an alternative for the ER-/HER2+ subtype due to its very limited number of cases), although its performance in this subtype is not as strong as in TNBC (Fig. 7).

An analysis of over 15,000 breast cancer patients shows that this gene signature is prognostic for both ER-negative/triple-negative (Figs. 1-6) and ER-positive (Figs. 7-9) breast cancers. It also predicts survival in HER2-amplified breast cancer (Fig. 10), although its predictive capability is relatively weaker in this subtype.

3. Signature Blue_response for breast cancer chemotherapy  

An analysis of approximately 6,000 cancer patients reveals that this gene signature effectively predicts pathological complete response to neoadjuvant chemotherapy （pCR） in patients with either ER-negative or ER-positive breast cancers (Fig. 1 - 3) .   Additionally, this gene signature is equally effective in accurately predicting pCR in HER2-amplified breast cancers treated with a combination of chemotherapy and anti-HER2 targeted therapy (Fig. 4 -6) . 

4. Signature Blue_OV for ovarian  cancer  

An analysis of approximately 3,500 cancer patients reveals that a high score of this gene signature is associated with reduced ovarian cancer sensitivity to chemotherapy (Fig. 1) and poorer survival outcomes for patients with this cancer (Figs. 2 and 3).

5. Signature Blue_CRC for colorectal cancer

An analysis of gene expression profile from over 6,000 samples shows that this gene signature is prognostic for patients with colorectal cancer.